Nelly Shishkova

Generex Biotechnology Corp. (OTC:GNBT) Keeps Running Up

by Nelly Shishkova January 18, 2012

Generex.gifAs of October 31, the liabilities of Generex were 50% higher than it total assets, its stockholders' deficiency exceeded $7 million, and its accumulated deficit remained over $347 million.

As the revenues of GNBT cannot cover the company's losses, the only option for Generex is to keep existing under a going concern until it finds additional financing to support its operations.

Type the characters that you see in the box (5 characters).